Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC
This is a Prospective, open label, single arm study to evaluate the efficacy and safety of Vebreltinib combined with Osimertinib in the treatment of locally advanced or metastatic non-small cell lung cancer with EGFR 21 L858R mutation
Non-Small-Cell Lung Cancer
DRUG: Vebreltinib|DRUG: Osimertinib
Progression-free survival, From the first treatment to the date of first documentation of disease progression, or death due to any cause, 3 years
Overall Response Rate, ORR is defined as the proportion of subjects with confirmed best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1., 3 years|Overall survival, From the first administration to death from any cause, 5 years|Duration of Response, DoR is defined as the time from the date of first documented response until date of documented progression per RECIST 1.1 as assessed by the investigator or death in the absence of disease progression., 3 years|Incidence of Treatment-Emergent Adverse Events, A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug., 3 years
This is a Prospective, open label, single arm study to evaluate the efficacy and safety of Vebreltinib combined with Osimertinib in the treatment of locally advanced or metastatic non-small cell lung cancer with EGFR 21 L858R mutation